
Please try another search
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Michael D. Blaszyk | 72 | 2015 | Independent Director |
Richard Gerald Adcock | 55 | 2020 | President, CEO & Director |
Cheryl L. Cohen | 58 | 2019 | Lead Independent Director |
Linda Maxwell | 49 | 2021 | Independent Director |
Barry J. Simon | 59 | 2007 | Chief Corporate Affairs Officer & Director |
Patrick Soon-Shiong | 71 | 2014 | Executive Chairman of the Board and Global Chief Scientific & Medical Officer |
Christobel E. Selecky | 70 | 2020 | Independent Director |
Wesley Kanne Clark | 81 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review